Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle

Dr. Tracy Marks discusses ketamine's role in treating depression, highlighting its rapid effects and recent developments. Ketamine, traditionally an anesthetic, is now recognized for its antidepressant properties, especially for treatment-resistant depression. The FDA-approved nasal spray Spravato has shown superior results compared to quetiapine. Despite initial skepticism, Spravato's effectiveness and potential insurance coverage make it a viable option. Recent studies also support ketamine injections as a cost-effective alternative. The video concludes with a look at future treatments like psilocybin.

What new insight or understanding did you gain from this video?